Cancer is ruthless. The system built to fight it? Often just as brutal, paperwork, phone tag, waiting rooms that drain energy patients don’t have. That’s the gap Thyme Care set out to close. Now, with $97M raised in Series D and a $1B valuation, they’ve got the fuel to take it national. Profitability already hit, $5B in oncology spend managed, and 8M people with access proves this model isn’t theory, it’s traction.
Thyme Care isn’t another “healthtech startup.” It’s value-based cancer care with teeth. Co-founders Robin Shah, CEO, and Dr. Bobby Green, President and CMO, didn’t conjure this overnight. Shah cut his teeth in his father’s oncology practice during the 2008 financial crisis, then drove strategy at Flatiron Health and co-founded OneOncology. Green led clinically as CMO at Flatiron after years as a practicing oncologist and partner at Palm Beach Cancer Institute. Together, they knew most cancer care happens outside the clinic, and built a system to navigate it with precision.
Investors clearly agree. This round was led by CVS Health Ventures, Foresite Capital, Andreessen Horowitz Bio + Health, Concord Health Partners, Town Hall Ventures, AlleyCorp, and Frist Cressey Ventures. Strategic players like Morgan Health, Humana, Texas Oncology, and Memorial Hermann also joined, signaling that both Wall Street and Main Street see Thyme Care as a necessary shift. When every prior investor doubles down, it’s not charity, it’s conviction.
The numbers say it all. Inpatient admissions down 19%. ER use cut 40% when patients complete ePRO surveys. A 95% success rate keeping patients out of the ER. That’s not incremental, it’s billions in savings and families spared chaos. Patients notice too, 9/10 rate their experience highly. For payers, providers, and employers battling runaway oncology costs, that’s the holy grail.
The tech makes it possible. Thyme Box integrates with EHRs, pulling data from everywhere. Thyme Care Signal delivers real-time insights. An AI orchestration layer reduces cognitive overload for care teams, turning noise into coordinated action. This is no bolt-on tool, it’s a purpose-built, HIPAA-compliant cloud platform designed to carry financial risk with clinical navigation. And the growth is undeniable, 1,000 oncologists already on board, with plans to quadruple cancer patient reach in 2025.
This round isn’t about keeping lights on. It’s about scaling a profitable company, growing 4x YoY, expanding into new markets, signing more payer and provider deals, and widening comprehensive cancer support. Shah and Green aren’t running a lab experiment, they’re running a movement. Cancer care has been running on fumes, and Thyme Care just dropped in a new engine.
